Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EGLT: 5.97 (+0.21), LNCO: 10.87 (-0.44), ASPS: 33.81 (+4.37), DERM: 19.65 (+0.38), MCEP: 6.07 (-0.12), GTIM: 6.13 (-0.07), LINE: 10.93 (-0.32), ORPN: 6.25 (-0.35), NYNY: 7.89 (+0.32), POZN: 7.86 (+0.07), OTIC: 32.26 (+0.65)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)
United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST
MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)
Egalet's (EGLT) CEO Bob Radie on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:18AM CST
EGLT: 5.97 (+0.21)
Egalet net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:29AM CST
EGLT: 5.97 (+0.21)
Egalet beats by $0.14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:41AM CST
EGLT: 5.97 (+0.21)
Egalet Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Wed Nov 12, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
EGLT: 5.97 (+0.21)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 12.65 (+0.66), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), AXN: 0.31 (+0.01), SRNE: 9.50 (+0.99), NKTR: 15.02 (+0.23), EGLT: 5.97 (+0.21), AZN: 70.44 (+0.26), VBAY: ()
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
GlobeNewswire - Wed Nov 05, 7:30AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.97 (+0.21)
Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November 12, 2014
PR Newswire - Wed Oct 29, 7:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
EGLT: 5.97 (+0.21)
FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT
MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)
2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 7.16 (+0.21), EGLT: 5.97 (+0.21)